LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Exacerbations de l'asthme chez la femme enceinte.

    Prudhomme, A / Frys, S / Tillie-Leblond, I

    Revue des maladies respiratoires

    2011  Volume 28, Issue 6, Page(s) 834–838

    Abstract: Prevention of exacerbations and effective treatment is essential in pregnant asthmatic women. The management is well documented. Misunderstanding of the recommendations leads to unsuitable, insufficient treatment and is responsible for more frequent ... ...

    Title translation Exacerbations of asthma in pregnant women.
    Abstract Prevention of exacerbations and effective treatment is essential in pregnant asthmatic women. The management is well documented. Misunderstanding of the recommendations leads to unsuitable, insufficient treatment and is responsible for more frequent recurrences in the pregnant woman compared with the non pregnant. Above all, good control of the disease and the prevention of exacerbations, based on inhaled corticosteroid therapy and smoking cessation, reduces complications, in particular prematurity and low birth weight.
    MeSH term(s) Anti-Asthmatic Agents/adverse effects ; Anti-Asthmatic Agents/pharmacology ; Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Asthma/physiopathology ; Asthma/therapy ; Cohort Studies ; Dyspnea/etiology ; Dyspnea/prevention & control ; Female ; Fetus/drug effects ; Humans ; Infant, Newborn ; Meta-Analysis as Topic ; Obesity/complications ; Obstetric Labor, Premature/prevention & control ; Oxygen Inhalation Therapy ; Pregnancy ; Pregnancy Complications/drug therapy ; Pregnancy Complications/physiopathology ; Pregnancy Complications/prevention & control ; Pregnancy Complications/therapy ; Recurrence ; Risk Factors ; Smoking Cessation
    Chemical Substances Anti-Asthmatic Agents
    Language French
    Publishing date 2011-06
    Publishing country France
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 605743-3
    ISSN 1776-2588 ; 0301-0279 ; 0761-8425
    ISSN (online) 1776-2588
    ISSN 0301-0279 ; 0761-8425
    DOI 10.1016/j.rmr.2010.12.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1945: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.

    Frys, Sarah / Simons, Zachary / Hu, Qiang / Barth, Matthew J / Gu, Juan J / Mavis, Cory / Skitzki, Joseph / Song, Liu / Czuczman, Myron S / Hernandez-Ilizaliturri, Francisco J

    British journal of haematology

    2015  Volume 169, Issue 4, Page(s) 506–519

    Abstract: Histone deacetylases (HDACs) inhibitors are active in T-cell lymphoma and are undergoing pre-clinical and clinical testing in other neoplasms. Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in ...

    Abstract Histone deacetylases (HDACs) inhibitors are active in T-cell lymphoma and are undergoing pre-clinical and clinical testing in other neoplasms. Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in haematological and solid tumour malignancies. To define the activity and biological effects of entinostat in B-cell lymphoma we studied its anti-tumour activity in several rituximab-sensitive or -resistant pre-clinical models. We demonstrated that entinostat is active in rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL) and primary tumour cells isolated from lymphoma patients (n = 36). Entinostat exposure decreased Bcl-XL (BCL2L1) levels and induced apoptosis in cells. In RSCL and RRCL, entinostat induced p21 (CDKN1A) expression leading to G1 cell cycle arrest and exhibited additive effects when combined with bortezomib or cytarabine. Caspase inhibition diminished entinostat activity in some primary tumour cells suggesting that entinostat has dual mechanisms-of-action. In addition, entinostat increased the expression of CD20 and adhesion molecules. Perhaps related to these effects, we observed a synergistic activity between entinostat and rituximab in a lymphoma-bearing severe combined immunodeficiency (SCID) mouse model. Our data suggests that entinostat is an active HDAC inhibitor that potentiates rituximab activity in vivo and supports its further clinical development in B-cell lymphoma.
    MeSH term(s) Animals ; Antibodies, Monoclonal, Murine-Derived/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; Benzamides/pharmacology ; Boronic Acids/pharmacology ; Bortezomib ; Cell Line, Tumor ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; Cytarabine/pharmacology ; Drug Resistance, Neoplasm/drug effects ; Female ; G1 Phase Cell Cycle Checkpoints/drug effects ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Lymphoma, B-Cell/drug therapy ; Lymphoma, B-Cell/metabolism ; Lymphoma, B-Cell/pathology ; Male ; Mice ; Mice, SCID ; Pyrazines/pharmacology ; Pyridines/pharmacology ; Rituximab ; Xenograft Model Antitumor Assays ; bcl-X Protein/metabolism
    Chemical Substances Antibodies, Monoclonal, Murine-Derived ; BCL2L1 protein, human ; Benzamides ; Boronic Acids ; CDKN1A protein, human ; Cyclin-Dependent Kinase Inhibitor p21 ; Histone Deacetylase Inhibitors ; Pyrazines ; Pyridines ; bcl-X Protein ; Cytarabine (04079A1RDZ) ; entinostat (1ZNY4FKK9H) ; Rituximab (4F4X42SYQ6) ; Bortezomib (69G8BD63PP)
    Language English
    Publishing date 2015-05
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.13318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top